New learning discoveries about (S)-4-(4-(5-(Aminomethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions. you can also check out more blogs about 446292-10-0. Product Details of 446292-10-0.

Chemistry, like all the natural sciences, Product Details of 446292-10-0, begins with the direct observation of nature¡ª in this case, of matter.446292-10-0, Name is (S)-4-(4-(5-(Aminomethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one, SMILES is O=C1N(C2=CC=C(N3C(O[C@@H](CN)C3)=O)C=C2)CCOC1, belongs to Isoxazoles compound. In a document, author is Adamovich, Sergey N., introduce the new discover.

Isoxazole derivatives of silatrane: synthesis, characterization, in silico ADME profile, prediction of potential pharmacological activity and evaluation of antimicrobial action

A new family of mono- (3a-h) and bis- (4a-g) isoxazole-bridged silatranes has been synthesized by the reaction of 3-aminopropylsilatrane (1) and 3-substituted 5-chloro-methylisoxazoles (2a-h). The structure of the isoxazole-silatrane hybrids is characterized by elemental analysis, FT-IR, UV, NMR (H-1,C-13,Si-29 and(15)N) spectroscopy, high-resolution mass spectrometry, and X-ray diffraction analysis. Thein silicoADME (absorption, distribution, metabolism, excretion) assessment reveals that properties of mono-adducts (3a-h) are similar to those of drugs obeyed to the Lipinski’s rule. The calculated screening of potential pharmacological activity profiles (in silicoPASS program) of isoxazole-silatranes shows that all synthesized compounds (both mono- and bis-substituted) may have high antitumor action, unlike starting isoxazoles. The preliminary screening of the synthesized silatranes for antimicrobial activity againstEnterococcus durans,Bacillus subtilis,Escherichia coli,andPseudomonas aeruginosaindicates that all test samples are active only against gram-positive microorganisms. Silatrane3fdisplays minimal inhibitory concentration (MIC 12.5 and 6.2 mu g ml(-1)) againstE. duransandB. subtilisas compared with standard drug gentamicin (MIC 25 and 50 mu g ml(-1)).

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions. you can also check out more blogs about 446292-10-0. Product Details of 446292-10-0.

Reference:
Isoxazole – Wikipedia,
,Isoxazole | C3H3NO – PubChem